IMMNOV — Immunovia AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK61.82m
- SEK30.19m
- SEK0.69m
Brief: Immunovia Set To Launch PancreaSure In U.S.
Brief: Immunovia Q1 Revenue SEK 139 Thousand
Brief: Immunovia Announces Determined Exercise Price For Warrants Series To 3
Brief: Immunovia Q4 Revenue SEK 455 Thousand
Brief: Immunovia Initiates Search For A New CFO To Support Commercialization In The USA
Brief: Immunovia Starts Search For New CFO To Support US Commercialization
Brief: Immunovia Announces Positive Outcome Of CLARITI Study
Brief: Immunovia Will Launch Next-Generation Test In 2025 H2
Brief: Immunovia Q3 Revenue SEK 235 Thousand
Brief: Immunovia Carries Out Directed Issue Of Units To Guarantors
Brief: Immunovia To Receive About SEK 63.2 Mln Through Completed Rights Issue
Brief: Immunovia Announces Final Terms Of Rights Issue
Brief: Immunovia's usTest To Be Part Of U.S. Pancreatic Cysts Study
Brief: Immunovia: Q2 Cash Flow From Operating Activities Down At SEK -26.7 Mln
Brief: Immunovia Q2 Revenue SEK 85 Thousand
Brief: Immunovia Says Carries Out A Rights Issue Of Units Of About SEK 70 Mln And Raises Bridge Loans
Brief: Immunovia Streamlines Lab Operations With Move To Research Triangle Park
Brief: Immunovia In Q4 Will Initiate A Large Clinical Validation Study
Brief: Immunovia Q1 Adjusted EPS SEK -0.07